Cardlytics (NASDAQ:CDLX) Lifted to “Buy” at Craig Hallum

Craig Hallum upgraded shares of Cardlytics (NASDAQ:CDLXFree Report) from a hold rating to a buy rating in a report released on Friday, Marketbeat reports. Craig Hallum currently has $18.00 price target on the stock, up from their prior price target of $10.00.

CDLX has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $12.00 price objective on shares of Cardlytics in a research report on Tuesday, January 30th. Lake Street Capital initiated coverage on Cardlytics in a report on Wednesday, November 29th. They issued a buy rating and a $13.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $11.60.

Get Our Latest Stock Report on Cardlytics

Cardlytics Trading Up 77.0 %

Cardlytics stock opened at $14.50 on Friday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.15 and a quick ratio of 1.15. Cardlytics has a one year low of $2.57 and a one year high of $19.57. The stock has a market capitalization of $569.18 million, a PE ratio of -1.19 and a beta of 1.36. The business’s fifty day moving average is $7.22 and its 200 day moving average is $10.04.

Insider Transactions at Cardlytics

In other news, major shareholder Clifford Sosin sold 17,155 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $7.00, for a total value of $120,085.00. Following the transaction, the insider now owns 5,361,961 shares of the company’s stock, valued at $37,533,727. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Clifford Sosin sold 17,155 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $7.00, for a total value of $120,085.00. Following the transaction, the insider now owns 5,361,961 shares of the company’s stock, valued at $37,533,727. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Karim Saad Temsamani sold 31,123 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $7.77, for a total value of $241,825.71. Following the completion of the transaction, the chief executive officer now directly owns 277,735 shares in the company, valued at approximately $2,158,000.95. The disclosure for this sale can be found here. Insiders have sold 136,556 shares of company stock valued at $926,492 over the last quarter. 0.78% of the stock is currently owned by company insiders.

Institutional Trading of Cardlytics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CDLX. Invesco Ltd. raised its stake in Cardlytics by 538.1% during the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after purchasing an additional 677,354 shares during the period. Norges Bank purchased a new position in Cardlytics during the 4th quarter valued at approximately $2,338,000. Two Sigma Advisers LP grew its holdings in Cardlytics by 664.7% during the 3rd quarter. Two Sigma Advisers LP now owns 459,600 shares of the company’s stock valued at $4,320,000 after buying an additional 399,500 shares in the last quarter. Baillie Gifford & Co. grew its holdings in Cardlytics by 30.7% during the 4th quarter. Baillie Gifford & Co. now owns 1,436,220 shares of the company’s stock valued at $8,301,000 after buying an additional 337,252 shares in the last quarter. Finally, UBS Group AG grew its holdings in Cardlytics by 210.5% during the 4th quarter. UBS Group AG now owns 174,822 shares of the company’s stock valued at $1,010,000 after buying an additional 332,961 shares in the last quarter. Institutional investors own 72.67% of the company’s stock.

Cardlytics Company Profile

(Get Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

See Also

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.